Article Text

PDF
Successful treatment of refractory adult onset Still’s disease with rituximab
  1. K Ahmadi-Simab,
  2. P Lamprecht,
  3. C Jankowiak,
  4. W L Gross
  1. Department of Rheumatology, University Hospital of Schleswig-Holstein, Campus Luebeck, and Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Luebeck, Germany
  1. Correspondence to:
    Dr K Ahmadi-Simab
    Germany; ahmadi{at}r-on-klinik.de

Statistics from Altmetric.com

We read with interest the article by Aarntzen et al1 reporting the inefficacy of anti-tumour necrosis factor (TNF) α inhibitor treatment with etanercept in adult onset Still’s disease (AOSD).

We found that etanercept and also infliximab were ineffective in two patients with AOSD. Both patients were subsequently successfully treated with the monoclonal anti-CD20 antibody rituximab, targeting B cells. In both cases AOSD was diagnosed according to American College of Rheumatology criteria. Major symptoms were polyarthritis, fever, and typical skin lesions. Despite successive treatment with prednisolone and methotrexate (MTX), ciclosporin, leflunomide, cyclophosphamide po, and intravenous immunoglobulin, the patients’ AOSD remained active, with recurrent febrile episodes, rash, synovitis, a serum ferritin level of 6400 μg/l (normal ⩽200), and a mean C reactive protein level of 82 mg/l (normal …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.